Medica Corp

MA - BedfordDiagnostics3 H-1B visas (FY2023)

Focus: Medica Corp is a Massachusetts-based diagnostics company founded in 1983 specializing in in-vitro diagnostic analyzers across oncology, cardiovascular, neurology, immunology, and hematology. The company maintains a diversified generic and branded pharmaceutical portfolio generating approximately $37M in peak revenue from TYRVAYA.

Oncology Cardiovascular Neurology Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

2+2 this month

Stable — net +2 jobs in 30d

2 added, 0 removed. Backfill posture.

5 recent layoff filings (12 mo) — 421 affected

1/30/2026 — San Diego, CA · 83 affected · Layoff Permanent
1/7/2026 — Pomona, CA · 108 affected · Layoff Permanent
1/7/2026 — Claremont, CA · 1 affected · Layoff Permanent
+2 more

Source: state DOL filings via Big Local News

Should You Work at Medica Corp?

AI assessment

Medica Corp presents a contracting, generic-heavy pharmaceutical business undergoing significant downsizing with limited pipeline innovation—suitable only for risk-tolerant candidates seeking supply chain or QA stability in a restructuring environment.

Why Work Here

Established 40+ year history in diagnostics provides operational stability and domain expertise across five therapeutic areas.

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

1 in 5yr

ZIPSOR

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

TYRVAYA

Not specified in data

$37M Part D

Peak9.3yr

Flagship NDA product generating one-third of company revenue with 10+ year patent exclusivity runway.

Help build intelligence for Medica Corp

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Peak-lifecycle product TYRVAYA (varenicline) generates $37M Part D spending with patent protection until 2035, supporting near-term revenue stability.

Perfect H1B sponsorship record (3 approvals, 0 denials in 2023) signals openness to international talent acquisition.

Watch Out For

Severe workforce contraction: 600+ employees laid off across six facilities in 2025-2026, including permanent closures in Willows CA (225 employees) and Herndon VA (162 employees), signaling major restructuring.
Only 2 active job openings (Quality Assurance, Supply Chain) despite massive headcount reductions indicates limited near-term hiring momentum.
Portfolio heavily dependent on post-LOE generics (imatinib mesylate, docetaxel, diclofenac) with minimal pipeline depth—only 20 clinical trials across all phases and no Phase 1 programs beyond early-stage oncology work.
Minor patent cliff exposure ($3M at risk from CAMBIA and ZIPSOR by 2029) combined with zero R&D intensity data and no recent FDA approvals suggests limited growth trajectory.

Generated by Claude from Medica Corp's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

IMATINIB MESYLATE

Chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST)

$36M and $21M Part D (separate SKUs)

Post-LOE

Post-exclusivity generic formulations collectively generating ~$57M Part D spending but facing commoditization pressure.

DIMETHYL FUMARATE

Relapsing forms of multiple sclerosis

$14M Part D

Pre-Launch

ANDA generic competitor to Tecfidera with pre-launch status suggesting near-term market entry and moderate revenue uplift potential.

CAMBIA

Migraine (implied)

$2M Part D

LOE ApproachingPost-LOE

Small-revenue NDA product losing exclusivity in 2026, contributing to near-term revenue erosion.

CHLORTHALIDONE

Hypertension management

$1M Part D

Post-LOE

Post-LOE diuretic generic with minimal revenue contribution.

ZIPSOR

Pain management

$797K Part D

LOE Approaching2.7yr

Small NDA product with patent expiration in 2029, representing minor revenue at risk.

DOCETAXEL

Metastatic breast cancer, non-small cell lung cancer

$699K Part D

Post-LOE

Post-LOE generic chemotherapy with minimal commercial revenue contribution.

DICLOFENAC POTASSIUM

Rheumatoid arthritis, primary dysmenorrhea

$690K Part D

Post-LOE

Post-LOE NSAID generic with modest revenue from multiple formulations.

DICLOFENAC POTASSIUM

Migraine

$690K Part D

Post-LOE

Separate SKU of post-LOE diclofenac generic contributing minimal incremental revenue.

Pipeline & Clinical Trials

ChitoCare® medical Wound Healing Gel

Dermatitis

N/A

Clinical Trials (1)

NCT06850389PMCF Investigation of Medical Device ChitoCare® Medical

N/A

Striatin

Malnourished Children

N/A

Clinical Trials (1)

NCT06933862Effects of Channa Striata Extract on Intestinal Inflammation and Nutritional Status in Malnutritional Toddlers After Albendazole Therapy in South Bangka District

N/A

Glimepiride

Chronic Heart Failure

N/A

Clinical Trials (1)

NCT05538819The Effects of Glimepiride in Patients With Type 2 Diabetes and Chronic Heart Failure

N/A

antiviral therapies for CMV and/or ADV

Infectious Complications Following HSCT

N/A

Clinical Trials (1)

NCT02873325Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT

N/A

Use of Molecular Breast Imaging (MBI) to Detect Additional Disease in Women With Breast Cancer Who A

Breast Cancer

N/A

Clinical Trials (1)

NCT00776308Use of Molecular Breast Imaging (MBI) to Detect Additional Disease in Women With Breast Cancer Who Are About to go to Surgery

N/A

magnetic facial nerve stimulation

Normal Subject / Healthy Volunteers

N/A

Clinical Trials (1)

NCT03487393VitalFlow Healthy Volunteer Study

N/A

Nasal swab

Inflammation

N/A

Clinical Trials (1)

NCT03311048Airway Inflammatory Profile Among Cleaning Workers From Different Workplaces

N/A

Hydrocortisone

Healthcare-Associated Pneumonia

N/A

Clinical Trials (1)

NCT05354778HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study

N/A

Screening in Myocardial Perfusion Patients

Breast Cancer

N/A

Clinical Trials (1)

NCT00943241Screening in Myocardial Perfusion Patients

N/A

HIBA-Institutional Registry of Amyloidosis

Amyloidosis

N/A

Clinical Trials (1)

NCT01347047HIBA-Institutional Registry of Amyloidosis

N/A

Glucose and lipids

Hyperlipidemia

N/A

Clinical Trials (1)

NCT02029989Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

N/A

Motilis-3D-transit

Ulcerative Colitis

N/A

Clinical Trials (1)

NCT01745029Gastrointestinal Motility in Severe Ulcerative Colitis Obtained by Motilis-3D-transit

N/A

Retrospective and Prospective Observational Study in Patients With Advanced Basal Cell Carcinoma

Basal Cell Carcinoma

N/A

Clinical Trials (1)

NCT06309836Retrospective and Prospective Observational Study in Patients With Advanced Basal Cell Carcinoma

N/A

Surgery with FACET FIXATION implants

Degenerative Lumbar Spinal Stenosis

N/A

Clinical Trials (1)

NCT05645497Evaluation of the Efficacy and Safety of the FACET FIXation Implant.

N/A

Computed Tomography Coronary Angiography (CTCA) Prognostic Registry for Coronary Artery Disease

Coronary Artery Disease

N/A

Clinical Trials (1)

NCT01384721Computed Tomography Coronary Angiography (CTCA) Prognostic Registry for Coronary Artery Disease

N/A

Nutritional counseling

Overweight

N/A

Clinical Trials (1)

NCT02887950Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause

N/A

Perindopril 4 mg tablets of PT Dexa Medica

Healthy

N/A

Clinical Trials (1)

NCT01682577Bioequivalence Study of Two Formulations of Perindopril 4 mg Tablet Under Fasting Condition

N/A

Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey

Cardiovascular Diseases

N/A

Clinical Trials (1)

NCT04508920A Survey to Assess Effects of Covid-19 on Cardiovascular Patients

N/A

Lisinopril 10 mg tablets of PT Dexa Medica

Healthy

N/A

Clinical Trials (1)

NCT01936012Bioequivalence Study of Two Formulations of 10 mg Lisinopril Tablet Under Fasting Condition

N/A

Pregabalin capsules 150 mg of Dexa Medica

Healthy

N/A

Clinical Trials (1)

NCT02233777Bioequivalence Study of Two Formulations of Pregabalin Capsules 150 mg

N/A

Treatment A

Perennial Allergic Rhinitis

N/A

Clinical Trials (1)

NCT05122143Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers

N/A

Non-pharmacological approach of insomnia

Insomnia

N/A

Motilis-3D transit

Ulcerative Colitis

N/A

Clinical Trials (1)

NCT01752361Gastrointestinal Transit Times and Motility in Severe Ulcerative Colitis Obtained by Motilis-3D-transit

N/A

Dapagliflozin 10 mg film-coated tablet

Healthy

N/A

Clinical Trials (1)

NCT06127212Bioequivalence Study of Dapagliflozin 10 mg Film-coated Tablets

N/A

Individualized educational program

Asthma

N/A

Clinical Trials (1)

NCT03655392Clinical, Functional and Inflammatory Evaluation in Asthmatic Patients After a Simple Short-Term Educational Program

N/A

Mirabilis System

Uterine Leiomyoma

N/A

Clinical Trials (1)

NCT03219385Directed Ablation of Uterine Fibroids Using a Noninvasive Approach

N/A

CeraVe Moisturizing Cream

Atopic Dermatitis (AD)

N/A

Clinical Trials (1)

NCT07204561CeraVe Effect on Restoring Skin Hydration as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis

N/A

colonoscopy

Inflammatory Bowel Diseases

N/A

Clinical Trials (1)

NCT05576402Endoscopic Scoring System Utilization in Inflammatory Bowel Disease

N/A

Cardiac Contractility Modulation

Chagas Cardiomyopathy

N/A

Clinical Trials (1)

NCT05519046Cardiac Contractility Modulation in Chagas Heart Disease

N/A

Rotational fractional resection

Skin Laxity

N/A

Clinical Trials (1)

NCT03407313CONFORM: Rotational Fractional Resection for Submental Contouring

N/A

topical treatment with the pre- and postbiotic study preparation and niacinamide 4% and one with the 10% urea-based preparation.

Xerosis Cutis

N/A

Clinical Trials (1)

NCT06868771Study on the Effectiveness of an Emollient Cream Containing Pre and Postbiotic and Niacinamide 4% in the Treatment of Skin Xerosis and Itching in Oncological Patients Treated with Anti-EGFR

N/A

Hormonal Effects on Tc-99m Sestamibi Uptake in the Breast

Breast Cancer

N/A

Clinical Trials (1)

NCT00943527Hormonal Effects on Tc-99m Sestamibi Uptake in the Breast

N/A

National Register of Moderate and Severe Adult Atopic Dermatitis

Atopic Dermatitis

N/A

Clinical Trials (1)

NCT06313333National Register of Moderate and Severe Adult Atopic Dermatitis

N/A

Focal Contouring System

Skin Laxity

N/A

Clinical Trials (1)

NCT03853980The INFORM Study: Rotational Fractional Resection for Submental Contouring

N/A

quadrivalent subunit influenza vaccine

Influenza Vaccine

N/A

Point of Care - Glycated Hemoglobin

Diabetes Mellitus, Type 2

N/A

Clinical Trials (1)

NCT05440968Comparative Effectiveness of POC-A1c vs the Current Standard Based on OGTT for Early Detection DM2 in Colombia

N/A

Low calorie diet treatment

Infertility

N/A

Clinical Trials (1)

NCT01566929Weight Management Intervention for Obese Women and the Live Birth Outcome of in Vitro Fertilization (IVF)

N/A

Upadacitinib

Atopic Dermatitis

N/A

Clinical Trials (1)

NCT05989932Real-world Experience on the Use of Upadacitinib in the Treatment of Moderate-severe Adult Atopic Dermatitis (ERUDA)

N/A

Mirabilis High-Intensity Focused Ultrasound Treatment System

Uterine Fibroids (Leiomyomas)

N/A

Clinical Trials (1)

NCT01946178Clinical Study of the Mirabilis High-Intensity Focused Ultrasound System for Non-Invasive Treatment of Uterine Fibroids

N/A

Rotational fractional resection

Skin Laxity

N/A

Clinical Trials (1)

NCT03966924The PREFORM Study: Rotational Fractional Resection for Submental Contouring

N/A

500 mg metformin hydrochloride extended release caplet

Metformin XR BE Study in Healthy Volunteers With Single and Multiple Dose

N/A

Clinical Trials (1)

NCT01677260Bioequivalence Study of Two Formulations of 500 mg Metformin Extended Release Tablet

N/A

Surgery

Breast Cancer

N/A

Clinical Trials (1)

NCT06447532Use of Machine Learning Techniques for Serial Assessment of Systemic Inflammatory Markers in Breast Cancer Patients

N/A

no interventions

Short Bowel Syndrome

N/A

Clinical Trials (1)

NCT04976075ImpRovE underSTanding of Short bOwel syndRome in Latin-amErica

N/A

18F-

Lung Cancer

N/A

Clinical Trials (1)

NCT035687994-[18F]Fluoroglutamine PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules

N/A

Liquid Chromatography-Mass Spectrometry Method to identify bilirubin molecular species

Hepatic Encephalopathy

N/A

Clinical Trials (1)

NCT05566548Role of Bilirubin Molecular Species in Hepatic Encephalopathy and Acute-on-chronic Liver Failure

N/A

Quikclot Radial

Coronary Artery Disease

N/A

Clinical Trials (1)

NCT03535597Hemostasis With QuikClot® Radial® Pad Versus TR Band® After Transradial Artery Access

N/A

cyclamax

Insomnia

N/A

Clinical Trials (1)

NCT00484497Evaluation of a Food Supplement on Sleep Quality

N/A

ClorNovir®

COVID-19

N/A

Valsartan 160 mg film-coated caplets

Healthy

N/A

Clinical Trials (1)

NCT02518451Bioequivalence Evaluation of Two Film-Coated Formulations of Valsartan 160 mg

N/A

data collection

Scabies

N/A

Clinical Trials (1)

NCT07305961National Study on the Epidemiology and Effectiveness of Therapies in the Treatment of Scabies

N/A

Interview Prep Quick Facts

Founded: 1983

Portfolio: 207 approved products, 147 clinical trials

Top TAs: Cardiovascular, Oncology, Respiratory

H-1B (2023): 3 approvals

Open Roles: 2 active jobs

Portfolio Health

Pre-Launch34 (16%)

Launch1 (0%)

Growth1 (0%)

Peak6 (3%)

LOE Approaching26 (13%)

Post-LOE139

Therapeutic Area Focus

Cardiovascular

44 marketed17 pipeline

Oncology

35 marketed22 pipeline

Respiratory

32 marketed18 pipeline

Neurology

30 marketed12 pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (6)

2026-01-30

83 employees affected— San Diego, CA

2026-01-07

108 employees affected— Pomona, CA

2026-01-07

1 employees affected— Claremont, CA

2026-01-07

4 employees affected— Pomona, CA

INTRAVENOUS · INJECTABLE

Radiopharmaceutical Activity

16 marketed17 pipeline

Metabolic Diseases

8 marketed19 pipeline

Immunology

16 marketed6 pipeline

Women's Health

2 marketed9 pipeline

225 employees affected— Willows, CA

2025-03-31

162 employees affected— Herndon VA, VA

Source: state DOL filings, aggregated via Big Local News

1 active drug shortage

Medica executed 600+ employee reductions across six facilities (San Diego, Pomona, Claremont, Willows CA and Herndon VA) between March 2025 and January 2026, including two permanent site closures, signaling severe operational restructuring.

Massive layoff footprint (600+ employees) combined with facility closures, zero FDA warning letters, but active drug shortage in Lorazepam Injection (supplier-side issue, not Medica-specific) indicates financial distress driving restructuring rather than quality/safety crises—still high departure risk for current employees.

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Medica Corp

Should You Work at Medica Corp?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (60)

Key Products by Revenue

Other Products (53)

Pipeline & Clinical Trials

Open Jobs (2)

Clinical Governance Administrator

Teleradiology Administrator

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (6)